Regenerative/anti-inflammatory (MSC)

Class

Cell therapy

Mesenchymal stem cells (MSCs) are multipotent stromal cells, typically sourced from bone marrow, adipose tissue, or umbilical cord tissue, that are being developed as cell therapies for conditions marked by tissue damage and chronic inflammation. Rather than primarily working by replacing lost cells through differentiation, MSCs are understood to act mainly through paracrine signaling: after administration, they secrete a broad mixture of growth factors, cytokines, and extracellular vesicles that can dampen excessive immune activation, recruit reparative cell types, and support the survival of stressed tissue. This dual regenerative and anti-inflammatory activity makes MSC-based therapies of interest across a range of disease contexts, including autoimmune and inflammatory disorders, graft-versus-host complications following transplantation, and degenerative conditions where ongoing tissue injury outpaces the body's own repair capacity. Because MSCs can sense their local environment and adjust their secreted factors in response to inflammatory signals, they are often described as environmentally responsive therapeutic agents rather than fixed-dose drugs. The rationale for this modality rests on the idea that a living cell can coordinate multiple complementary biological effects simultaneously, in contrast to a single-target molecule that engages one pathway at a time. This breadth is both the appeal and the central scientific challenge of the approach.